C013 | AN ITALIAN MULTICENTER RETROSPECTIVE OBSERVATIONAL STUDY TO ASSESS EFFECTIVENESS AND SAFETY OF ZANUBRUTINIB FOR PATIENTS WITH MARGINAL ZONE LYMPHOMA TREATED IN ITALY UNDER THE NAMED PATIENT PROGRAM – ZANOS STUDY

The primary analysis of MAGNOLIA, which led to drug approval, demonstrated that the next-generation BTK inhibitor zanubrutinib provided a high overall response rate (ORR) in patients with relapsed/refractory marginal zone lymphoma (R/R MZL), with a favorable safety/tolerability profile. Zanubrutini...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	V. Stefoni, A. Broccoli, L. Argnani, S. Blandino, F. Forte, G. Catania, V. Usai, V. Innao, A. Figuera, E. Martino, G. Daghia, B. Puccini, F. Malaspina, G. Lolli, M. Deodato, G. Scalpinello, D. Marino, M. Musso, M. Porrazzo, M. Cimminiello, M. Nizzoli, V. Rapisarda, L. Petrucci, C. Vitale, E. Lucchini, R. Plos, I. Ferrarini, S. Usai, P.L. Zinzani
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Ferrata Storti Foundation 2025-09-01
Rangatū:	Haematologica
Urunga tuihono:	https://haematologica.org/article/view/12877
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!